• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

Heart Failure Association - Heart Failure (ESC-HF HFA) - 2025

May 17 - 20, 2025

  1. Forxiga (dapagliflozin)
  2. Heart Failure/Chronic Kidney Disease
  3. ATTR amyloidosis
  4. Sodium Zirconium Cyclosilicate

HTML

Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial

PDF

Dapagliflozin for HFrEF: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study

pdf

Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with Preserved Ejection Fraction: the SOGALDI-PEF trial

PDF

Cardiorenal pathways and characteristics of patients with coexisting heart failure and chronic kidney disease (The CaRe Study)

pdf

Treatment patterns and clinical outcomes following diagnosis in patients with ATTR amyloidosis – results from the OverTTuRe study

pdf

Early clinical manifestations and time-to-diagnosis in patients with ATTR amyloidosis with mixed phenotype – results from the OverTTuRe study

PDF

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimisation in heart failure with reduced ejection fraction: the REALIZE-K open-label run-In phase

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No